KEWALRAMANI RESHMA (CEO & President) sold 28.9% of their position (40K shares) of VERTEX PHARMACEUTICALS INC / MA on the open market
Open‑market sale worth $19.74M — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
−400.00
Price / share
$479.75
Trade value
$191.90K
% of position
Common Stock
Shares
−120.00
Price / share
$481.50
Trade value
$57.78K
% of position
Common Stock
Shares
−240.00
Price / share
$482.84
Trade value
$115.88K
% of position
Common Stock
Shares
−2.51K
Price / share
$487.13
Trade value
$1.22M
% of position
Common Stock
Shares
−3.28K
Price / share
$488.27
Trade value
$1.60M
% of position
Common Stock
Shares
−460.00
Price / share
$489.32
Trade value
$225.09K
% of position
Common Stock
Shares
−2.73K
Price / share
$490.54
Trade value
$1.34M
% of position
Common Stock
Shares
−949.00
Price / share
$491.30
Trade value
$466.24K
% of position
Common Stock
Shares
−2.52K
Price / share
$493.29
Trade value
$1.24M
% of position
Common Stock
Shares
−3.50K
Price / share
$494.33
Trade value
$1.73M
% of position
Common Stock
Shares
−15.58K
Price / share
$495.38
Trade value
$7.72M
% of position
Common Stock
Shares
−6K
Price / share
$496.16
Trade value
$2.97M
% of position
Common Stock
Shares
−1.73K
Price / share
$496.95
Trade value
$857.24K
% of position
Net shares
−40K
Net value
-$19.74M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/27/2026 | S · Sale | −400.00 | $479.75 | $191.90K | 0.3% | 138.28K | 137.88K |
| Common Stock Direct | 2/27/2026 | S · Sale | −120.00 | $481.50 | $57.78K | 0.1% | 137.88K | 137.76K |
| Common Stock Direct | 2/27/2026 | S · Sale | −240.00 | $482.84 | $115.88K | 0.2% | 137.76K | 137.52K |
| Common Stock Direct | 2/27/2026 | S · Sale | −2.51K | $487.13 | $1.22M | 1.8% | 137.52K | 135.01K |
| Common Stock Direct | 2/27/2026 | S · Sale | −3.28K | $488.27 | $1.60M | 2.4% | 135.01K | 131.73K |
| Common Stock Direct | 2/27/2026 | S · Sale | −460.00 | $489.32 | $225.09K | 0.3% | 131.73K | 131.27K |
| Common Stock Direct | 2/27/2026 | S · Sale | −2.73K | $490.54 | $1.34M | 2.1% | 131.27K | 128.54K |
| Common Stock Direct | 2/27/2026 | S · Sale | −949.00 | $491.30 | $466.24K | 0.7% | 128.54K | 127.60K |
| Common Stock Direct | 2/27/2026 | S · Sale | −2.52K | $493.29 | $1.24M | 2.0% | 127.60K | 125.08K |
| Common Stock Direct | 2/27/2026 | S · Sale | −3.50K | $494.33 | $1.73M | 2.8% | 125.08K | 121.58K |
| Common Stock Direct | 2/27/2026 | S · Sale | −15.58K | $495.38 | $7.72M | 12.8% | 121.58K | 106K |
| Common Stock Direct | 2/27/2026 | S · Sale | −6K | $496.16 | $2.97M | 5.7% | 106K | 100K |
| Common Stock Direct | 2/27/2026 | S · Sale | −1.73K | $496.95 | $857.24K | 1.7% | 100K | 98.28K |
| Total | −40K | -$19.74M | ||||||